Enliven Therapeutics medical chief sells 5,000 shares

Q: How many ELVN shares did Helen Louise Collins sell, and at what price?

Helen Louise Collins sold 5,000 shares on October 19, 2026, at a weighted average price of $38.4684 per share. The sale involved multiple trades priced from $37.785 to $38.75.

Q: How many ELVN shares remained subject to Helen Louise Collins's options after the exercise?

The option transaction row reports 101,268 shares subject to the option following the October 19, 2026 exercise. The option's stated expiration date was June 17, 2031.

The chief medical officer's option exercise and same-day sale were effected under a Rule 10b5-1 plan adopted October 19, 2025.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Enliven Therapeutics, Inc. (ELVN) Chief Medical Officer Helen Louise Collins exercised options for 5,000 shares at an exercise price of $2.48 per share on October 19, 2026, and sold 5,000 shares the same day at a weighted average price of $38.4684 per share. The sale involved multiple trades priced from $37.785 to $38.75. The option exercise and sale were effected under a Rule 10b5-1 trading plan adopted October 19, 2025. Following the exercise, the option row reported 101,268 shares subject to the option.

Insider Trade Summary 10b5-1

Exercise and Sale: 5,000 shares ($180K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Collins Helen Louise

Role CHIEF MEDICAL OFFICER

Sold 5,000 shs ($192K)

Approx. gross sale proceeds $192K

Approx. exercise cost $12K

Approx. pre-tax spread $180K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) ^{F1, F5}	5,000	$0.00	$0.00
Exercise	Common Stock ^{F1, F2}	5,000	$2.48	$12K
Sale	Common Stock ^{F1, F3, F4}	5,000	$38.4684	$192K

Holdings After Transaction: Stock Option (right to buy) — 101,268 contracts (Direct); Common Stock — 25,000 shares (Direct)

Footnotes (5)

F1. The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.
F2. Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F3. This transaction was executed in multiple trades at prices ranging from $37.785 to $38.75. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4. These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F5. All of the shares subject to this option are fully vested and exercisable as of the date hereof.

Key Figures

Options exercised: 5,000 shares Option exercise price: $2.48 per share Shares sold: 5,000 shares +4 more

7 metrics

Options exercised 5,000 shares October 19, 2026

Option exercise price $2.48 per share October 19, 2026 exercise

Shares sold 5,000 shares October 19, 2026

Weighted average sale price $38.4684 per share October 19, 2026 sale

Sale price range $37.785 to $38.75 per share Multiple trades on October 19, 2026

Shares subject to option following exercise 101,268 shares Reported following the October 19, 2026 exercise

Option expiration date June 17, 2031 Option exercised on October 19, 2026

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, fully vested and exercisable

3 terms

Rule 10b5-1 trading plan regulatory

"effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"reflects the weighted average sale price"

fully vested and exercisable financial

"fully vested and exercisable as of the date hereof"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ELVN shares did Helen Louise Collins sell, and at what price?

Helen Louise Collins sold 5,000 shares on October 19, 2026, at a weighted average price of $38.4684 per share. The sale involved multiple trades priced from $37.785 to $38.75.

How many ELVN shares remained subject to Helen Louise Collins's options after the exercise?

The option transaction row reports 101,268 shares subject to the option following the October 19, 2026 exercise. The option's stated expiration date was June 17, 2031.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/21/2026 - 05:52 PM EDT Accepted by SEC EDGAR 10/21/2026 - 05:51 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Collins Helen Louise

(Last)

(First)

(Middle)

C/O ENLIVEN THERAPEUTICS, INC.

205 PARK ROAD

(Street)

BURLINGAME

CALIFORNIA

94010

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF MEDICAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/19/2026		M⁽¹⁾		5,000	A	$2.48	30,000⁽²⁾	D
Common Stock	10/19/2026		S⁽¹⁾		5,000	D	$38.4684⁽³⁾	25,000⁽⁴⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$2.48	10/19/2026		M⁽¹⁾			5,000	⁽⁵⁾	06/17/2031	Common Stock	5,000	$0	101,268	D

Explanation of Responses:

1. The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.

2. Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

3. This transaction was executed in multiple trades at prices ranging from $37.785 to $38.75. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

4. These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

5. All of the shares subject to this option are fully vested and exercisable as of the date hereof.

	/s/ Ben Hohl, by power of attorney	10/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR